Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudeep PharmaBOM:544619 -1.10%18 Pretax Margin % is 35.05% as of Mar. 2026, which is 3% below its 10-year median of 36.23. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Sudeep Pharma ranks better than 94.38% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Sudeep Pharma's Pre-Tax Income for the
three
months ended in Mar. 2026 was ₹627 Mil. Sudeep Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹1,789 Mil. Therefore, Sudeep Pharma's pretax margin for the quarter that ended in Mar. 2026 was 35.05%.
The historical rank and industry rank for Sudeep Pharma's Pretax Margin % or its related term are showing as below:
BOM:544619'
s Pretax Margin % Range Over the Past 10 Years
Min: 20.18 Med: 36.23 Max: 38.45
Current: 35.45
BOM:544619's Pretax Margin % is ranked better than 94.38% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.06
vs BOM:544619: 35.45
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Sudeep Pharma Pretax Margin % Related Terms
Sudeep Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Sudeep Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudeep Pharma Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Sudeep Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudeep Pharma (BOM:544619) has a Pretax Margin % of 35.05% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sudeep Pharma and its competitors. This is near median its historical median of 36.23. Over the past decade, Sudeep Pharma's Pretax Margin % has ranged from 20.18 to 38.45. According to the industry distribution chart, Sudeep Pharma ranks #54 out of 961 companies in the Drug Manufacturers industry, placing it in the top 5.6%.
Is Sudeep Pharma's Pretax Margin % too high?
Sudeep Pharma's current Pretax Margin % of 35.05% is near median its 10-year median of 36.23. Over the past 10 years, this metric has ranged from a low of 20.18 to a high of 38.45. The Drug Manufacturers industry median Pretax Margin % is 7.06. Sudeep Pharma's value of 35.05% is 396.5% above this industry median. Based on the distribution chart, Sudeep Pharma ranks #54 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #54 out of 961 companies for Pretax Margin %. This places Sudeep Pharma in the top 6% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.06. Sudeep Pharma's value of 35.05% is 396.5% above this benchmark. Historically, Sudeep Pharma's own Pretax Margin % has ranged from 20.18 to 38.45 over the past decade. While the company's 10-year median is 36.23 vs. the industry median of 7.06, Sudeep Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.06, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudeep Pharma's current Pretax Margin % of 35.05% is 396.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Sudeep Pharma and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudeep Pharma's current Pretax Margin % is 35.05%, which is near median its own 10-year median of 36.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current Pretax Margin % of 35.05%. The current Pretax Margin % is 35.05%, which is near median its 10-year median of 36.23 and 396.5% above the Drug Manufacturers industry median of 7.06. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current Pretax Margin % is 35.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score
Get the complete analysis for BOM:544619
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544619 has been successfully added to your 
